<DOC>
	<DOCNO>NCT00503243</DOCNO>
	<brief_summary>The aim study investigate safety efficacy SPD476 2.4 g/day give twice daily ( [ BID ] ie 1.2 g/day BID ) SPD476 4.8g/day give QD compare placebo subject acute , mild moderate ulcerative colitis .</brief_summary>
	<brief_title>Safety Efficacy SPD476 ( Mesalazine ) Given Twice Daily ( 2.4 g/Day ) v SPD476 Given Single Dose ( 4.8 g/Day ) Subjects With Acute Mild Moderate Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>newly diagnose diagnosis relapsing ( relapse &lt; = 6 week baseline ) mild moderate ulcerative colitis woman childbearing potential WOCP agree use effective contraceptive method severe ulcerative colitis relapse &gt; 6 week prior baseline subject relapse maintenance therapy dose mesalazine &gt; 2.0 g/day subject Crohn 's disease , proctitis , bleed disorder active peptic ulcer disease subject asthma know mesalazinesensitive subject immediate significant risk toxic megacolon subject previous resective colonic surgery subject moderate severe renal impairment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>